Purchase of pharmaceuticals which treat the underlying cause of cystic fibrosis (CFTR modulators)

Information

15 - Voluntary ex ante transparency notice
04.10.2018 09:18 (GMT+02:00)

Buyer

Amgros I/S Amgros I/S
Jon Bjergfelt Jon Bjergfelt
Dampfærgevej 22
2100 København Ø
Dänemark

Assignment text

Cystic fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused by the presence of mutations in both copies of the gene for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein. Today, patients with cystic fibrosis are mainly treated with pharmaceuticals which reduce the symptoms of cystic fibrosis without treating their underlying cause. Amgros wishes to enter into a contract ensuring that public hospitals in Denmark, Greenland and the Faroe Islands will be able to offer all their cystic fibrosis patients treatment with pharmaceuticals, which treat the underlying cause of cystic fibrosis (CFTR modulators).

Mercell Germany

Part of the Mercell Group, one of Europe’s leading providers of e tender systems and information between buyers and suppliers in the professional market.

Contact us

Write to us

+47 21 01 88 60
Mercell Germany | Askekroken 11, 0277 OSLO, Norwegen